On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of global harmonization and streamlining biosimilar development during a panel ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and ...

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...

At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...

At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...

At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

Sarfaraz K. Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing ...